24Jan 2023
Antibody response, neutralizing potency, and transplacental antibody transfer following SARS‐CoV‐2 infection versus mRNA‐1273, BNT162b2 COVID‐19 vaccination in pregnancy

Antibody response, neutralizing potency, and transplacental antibody transfer following SARS‐CoV‐2 infection versus mRNA‐1273, BNT162b2 COVID‐19 vaccination in pregnancy

To improve the understanding of the immune response, including the neutralization antibody response, following COVID-19 vaccination in pregnancy. Nearly all patients had detectable RBD-binding IgG in maternal and cord samples. The vaccinated versus infected cohort had a significantly higher proportion of cord samples with detectable neutralizing antibodies and significantly higher transfer ratios for RBD‐specific IgG and neutralizing antibodies, with a transfer efficiency of 105% and 110%, respectively. There was a significant linear decline in maternal and cord blood RBD-specific IgG and neutralizing antibody titers as time from vaccination to delivery increased. Those who receive the mRNA COVID‐19 vaccine mount an immune response equivalent to—if not greater than those naturally infected by SARS‐CoV‐2 during pregnancy.

  • #gynaecology - ivf

Like

Save

Share